MedDataX Logo

Clinical Trial of Quantitative Detection Kit for Hsp90α in Breast Cancer

NCT ID: NCT02324101

Last Updated: 2014-12-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

1100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-04-30

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Detect plasma Hsp90α concentration of breast cancer patients, healthy volunteers, benign breast diseases patients

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Detect plasma Hsp90α concentration of breast cancer patients, healthy volunteers, benign breast diseases patients, validate accuracy, specificity and sensitivity of Hsp90α kit.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Breast cancer

Detect plasma Hsp90α concentration of breast cancer patients

Group Type EXPERIMENTAL

Hsp90

Intervention Type DEVICE

Detect plasma Hsp90α concentration

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hsp90

Detect plasma Hsp90α concentration

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Biomarker

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* breast cancer patients, healthy volunteers, benign breast diseases patients

Exclusion Criteria

* Patients who previously received radiotherapy
Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Protgen Ltd

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Zhongsheng Tong, MD

Role: PRINCIPAL_INVESTIGATOR

Tianjin cance hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tianjin cancer hospital

Tianjin, Tianjin Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Zhongsheng Tong, MD

Role: CONTACT

Phone: 022

Fei Wu, MD

Role: CONTACT

Phone: 010

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Zhongsheng Tong, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

hsp90a2011-02

Identifier Type: -

Identifier Source: org_study_id